Voyager taps Brammer and Fujifilm for gene therapy development program

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/daizuoxin)
(Image: Getty/daizuoxin)

Related tags: CDMO, Brammer Bio, Fujifilm diosynth biotechnologies, Gene therapy, Manufacturing

The clinical-stage gene therapy company Voyager Therapeutics has entered into collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to expand its manufacturing capabilities.

Voyager will transfer its research and development production capabilities to the contract development and manufacturing organizations (CDMOs), which will support the development of its gene therapy programs, providing late-stage clinical and commercial-scale capabilities.

Voyager will lead early-stage development and scale-up before transferring the technology. The company’s manufacturing platform uses a baculovirus/Sf9 cell production process to produce clinical and commercial scale batches of adeno-associated virus (AAV) vectors.

The length of the collaboration has not specifically been disclosed, though it could be renewed based on meeting set milestones and other criteria, a spokesperson told us.

"Voyager plans to use [the CDMOs] to support the clinical development of its programs and if its programs are approved, for commercial supply,"​ they added.

In line with the collaboration announcement, Voyager will partner with Brammer to implement a commercial-ready manufacturing process under current good manufacturing practice (cGMP) at its Cambridge facility. At this facility and others, Brammer recently has completed a series of expansions​ as part of its three-year, $200m investment program.

Voyager also will partner with Fujifilm​ to provide first-in-human (FIH) cGMP clinical trial material production capacity at the CDMO’s College Station facility in Texas.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more